BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
1493 results:

  • 1. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
    Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
    J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
    Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
    Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without EGFR or ALK Alterations.
    Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
    Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
    Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
    Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-lung01): primary results of the her2-overexpressing cohorts from a single-arm, phase 2 trial.
    Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
    Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [A Case of Breast cancer That Developed Pulmonary Tumor Thrombotic Microangiopathy during Adjuvant Chemotherapy].
    Okano K; Suzuki T; Abe A; Itaya A; Kameyama Y; Matsumoto S; Hakamada K
    Gan To Kagaku Ryoho; 2024 Mar; 51(3):283-285. PubMed ID: 38494809
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Advances in the treatment of anti-her-2 antibody drug conjugates in pan-tumor with low her-2 expression].
    Wei T; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):211-220. PubMed ID: 38494768
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The Role of
    Chu J; Tang S; Li T; Fan H
    Front Biosci (Landmark Ed); 2024 Feb; 29(2):73. PubMed ID: 38420798
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. EGFR and erbb2 Exon 20 Insertion Mutations in Chinese Non-small Cell lung cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic treatment Evaluation.
    Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
    Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
    Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
    BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant her2-positive breast cancer lung metastasis model.
    Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
    Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. miRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting erbb2.
    Li L; Zhang Y; Yang K; Liu W; Zhou Z; Xu Y
    Cancer Rep (Hoboken); 2024 Feb; 7(2):e1974. PubMed ID: 38351535
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Leucine Zipper Downregulated in cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell lung cancer.
    Huang HN; Hung PF; Chen YP; Lee CH
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338651
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell lung cancer.
    Kanasaki H; Ozawa Y; Nakamura N; Nagasaki K; Matsuyama W; Akahori D; Niwa M; Ogasawara T; Sato J
    Anticancer Res; 2024 Feb; 44(2):723-730. PubMed ID: 38307579
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [A Case of Advanced Recurrent Rectal cancer Successfully Treated by Rechallenge Therapy with an Anti-Epidermal Growth Factor Receptor(EGFR)Drug].
    Sakuma T; Shibutani M; Fukuoka T; Kasashima H; Nishiyama M; Fukui Y; Natsuki S; Nishiyama T; Maruo K; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Maeda K
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1504-1506. PubMed ID: 38303322
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [A Case of Combined Use of Mohs Paste and Radiation Therapy for Advanced Breast cancer with Bleeding].
    Yanagawa T; Yamaura M; Nomura H; Oshima K; Katsuyama S; Shinke G; Kinoshita M; Ikeshima R; Hiraki M; Ohmura Y; Sugimura K; Masuzawa T; Hata T; Takeda Y; Murata K
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1839-1841. PubMed ID: 38303225
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [A Case of Triple Negative Breast cancer with Successful Control of Recurrent Disease Activity for More than Ten Years].
    Yabe N; Watanuki R; Harada Y; Kondo A; Yanagisawa T; Maeda H; Kishi M; Yoshikawa T; Osumi K; Kamiya N; Sotome K; Ishii Y; Jinno H; Ikeda T; Watanabe M
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1759-1761. PubMed ID: 38303198
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. lung toxicity induced by anti-her2 antibody - drug conjugates for breast cancer.
    Chai M; Li L; Wu H; Liu Y; Yi Z; Yu H
    Crit Rev Oncol Hematol; 2024 Mar; 195():104274. PubMed ID: 38295890
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
    Wang WN; Liu XT; Liang YM
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
    [No Abstract]    [Full Text] [Related]  

  • 20. Efficacy of immunotherapy in her2-mutated non-small cell lung cancer: a single-arm meta-analysis.
    Zhang J; Han W; Guo J; Zhang C; Cao L; Peng L; Han X; Wang Z
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):42. PubMed ID: 38280966
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 75.